ISPE iSpeak博文:AI洞察扩展药品CMC工艺验证与质量框架(第一部分)
扩展药品质量框架--AI洞察跨CMC工艺验证与质量体系
ISPE iSpeak 2026-11-09 博文探讨AI与机器学习如何扩展药品CMC工艺验证与质量框架,第一部分覆盖CPP识别与CQA–CPP关系建模。文章提出AI应在科学论证、基于风险并经验证的框架内实施,其价值在于延展工艺理解深度与速度而非取代既有制药科学。全文共三部分,另涵盖动态控制策略、AI模型验证与生命周期管理、检查就绪度及偏差管理等六项应用。
制药 AI 现场观察 | 主体材料:ISPE iSpeak(2026-11-09) 来源:ISPE iSpeak Blog URL:https://ispe.org/pharmaceutical-engineering/ispeak/expanding-pharmaceutical-quality-framework-part-1-leveraging-ai 日期:2026-11-09 作者:Robert Dream 说明:原文为三部分系列的第一部分(覆盖第 1、2 节),本稿全文对照。
题图:ISPE iSpeak 原文页官方配图(图库素材照,非制药设施实拍;图源:ispewebassets.org)
Artificial Intelligence (AI) and machine learning (ML) are reshaping how pharmaceutical organizations understand, develop, manufacture, and control medicinal products. Their potential extends beyond process optimization: AI-derived insights can strengthen pharmaceutical chemistry, manufacturing, and controls (CMC), support process validation, improve quality risk management, and enhance inspection readiness.
人工智能(AI)与机器学习(ML)正在重塑制药企业理解、开发、生产和控制药品的方式。其潜力不止于工艺优化:AI 派生的洞察可以强化药学 CMC(化学、制造与控制),支持工艺验证,改进质量风险管理,并提升检查就绪度。
But can AI-derived insights reliably support the identification of critical process parameters (CPPs), the characterization of critical quality attribute (CQA) relationships, the development of control strategies, the validation of AI models, and the investigation of deviations?
但 AI 派生洞察是否足以可靠地支持关键工艺参数(CPP)的识别、关键质量属性(CQA)关系的表征、控制策略的开发、AI 模型的验证以及偏差调查?
AI shows promise when implemented within a scientifically justified, risk-based, and appropriately validated framework. Structured experimentation, statistical modeling, and established quality engineering principles have long supported pharmaceutical development and remain essential. Yet modern manufacturing increasingly combines complex, nonlinear interactions, high-frequency sensor data, raw material variability, and interconnected operations that can strain conventional analytical methods.
AI 在科学论证充分、基于风险并经过适当验证的框架内实施时是有前景的。结构化实验、统计建模和成熟的质量工程原则长期支撑着制药开发,且仍然不可或缺。然而,现代生产日益叠加了复杂的非线性相互作用、高频传感器数据、原料变异性与相互关联的工序,这些都会让传统分析方法捉襟见肘。
AI offers new opportunities to identify hidden relationships, detect emerging risks, predict quality outcomes, and support more proactive quality management. Its greatest value lies not in replacing established pharmaceutical science, but in extending the depth and speed of process understanding.
AI 为识别隐藏关系、发现新出现的风险、预测质量结果和支持更主动的质量管理提供了新机会。它最大的价值不在于取代成熟的制药科学,而在于延展工艺理解的深度与速度。
This blog post (in three parts) explores six areas in which AI-derived insights can contribute to a more predictive, adaptive, and data-driven pharmaceutical quality framework:
本博文(共三部分)探讨 AI 派生洞察可以在哪些六个领域促成更具预测性、更自适应、更数据驱动的药品质量框架:
1. CPP identification
2. CQA–CPP relationship modeling
3. Dynamic control strategy development
4. AI model validation and lifecycle management
5. Inspection readiness and regulatory compliance
6. AI-supported deviation management and root cause analysis
7. Bridging the six applications together
8. Practical roadmap for industry
1. CPP 识别
2. CQA–CPP 关系建模
3. 动态控制策略开发
4. AI 模型验证与生命周期管理
5. 检查就绪度与监管合规
6. AI 支持的偏差管理与根本原因分析
7. 六项应用的贯通
8. 面向行业的实践路线图
Section 1 and 2 are covered in part 1;
Sections 3, 4 and 5 are covered in part 2;
Sections 6, 7 and 8 are covered in part 3.
第 1、2 节由本部分覆盖;第 3、4、5 节由第二部分覆盖;第 6、7、8 节由第三部分覆盖。
The central question is how pharmaceutical organizations can translate these capabilities into demonstrable product quality, process robustness, and regulatory confidence.
核心问题在于:制药企业如何把这些能力转化为可证明的产品质量、工艺稳健性和监管信心。
一、关键工艺参数识别 Critical Process Parameter Identification
为什么传统方法可能不够 Why Traditional Approaches May Be Insufficient
International Council for Harmonisation (ICH) guideline Q8(R2) defines a CPP as a process parameter whose variability affects a CQA and therefore requires monitoring or control to ensure the process produces the desired quality.
国际协调理事会(ICH)Q8(R2) 指南将 CPP 定义为其变异性会影响 CQA、因而需要监测或控制以保证工艺产出预期质量的工艺参数。
Design of experiments (DoE), regression analysis, and multivariate statistical techniques remain foundational tools for identifying these relationships. They provide structured experimental evidence and help establish the scientific basis for pharmaceutical process understanding. However, experimental complexity can increase rapidly as the number of parameters and their interactions grows. Although fractional factorial designs and other efficient experimental strategies help reduce the number of required runs, certain interactions may remain unexplored when experimental resources are limited.
实验设计(DoE)、回归分析和多变量统计技术仍是识别这些关系的基础工具。它们提供结构化的实验证据,并帮助建立制药工艺理解的科学基础。但随着参数数量及其交互作用增长,实验复杂性会迅速上升。尽管部分析因设计等高效实验策略有助于减少所需运行次数,但在实验资源有限时,某些交互作用可能始终未被探索。
Consider a biopharmaceutical process involving temperature, pH, agitation, dissolved oxygen, nutrient feed rate, raw material variability, equipment condition, and environmental factors. A parameter that appears insignificant during nominal operation may become important when another parameter shifts.
设想一个涉及温度、pH、搅拌、溶氧、补料速率、原料变异性、设备状态与环境因素的生物制药工艺。某个在标称运行下看似无关紧要的参数,可能在另一个参数发生偏移时变得重要。
For example, a change in raw material viscosity could alter mixing efficiency and oxygen transfer. Under certain conditions, this interaction could affect cell growth, product yield, or product quality.
例如,原料黏度的变化可能改变混合效率与氧传递。在特定条件下,这种交互作用可能影响细胞生长、产品收率或产品质量。
The challenge is not simply to identify influential parameters. It is to understand when, where, and under what conditions those parameters become critical.
挑战不只是识别有影响的参数,而是理解这些参数在何时、何地、何种条件下变得关键。
AI 与 ML 如何扩展参数发现 How AI and ML Expand Parameter Discovery
AI models can analyze historical batch manufacturing records, electronic batch records, process sensor data, environmental monitoring results, equipment maintenance histories, and raw material certificates of analysis (CoAs).
AI 模型可以分析历史批生产记录、电子批记录、工艺传感器数据、环境监测结果、设备维护历史以及原料分析证书(CoA)。
When these datasets are sufficiently representative, reliable, and appropriately governed, AI can help identify patterns that might not be apparent through conventional univariate analysis.
当这些数据集足够具有代表性、可靠并得到适当治理时,AI 可以帮助识别常规单变量分析难以察觉的模式。
Three capabilities are particularly valuable.
三项能力尤其有价值。
Feature Importance and Explainable AI 特征重要性与可解释 AI
Tree-based ensemble methods, such as Random Forests and Extreme Gradient Boosting (XGBoost), can rank input variables according to their predictive contribution. Shapley Additive Explanations (SHAP) can further help explain how individual variables contribute to model predictions.
基于树的集成方法,如随机森林和极端梯度提升(XGBoost),可以按预测贡献对输入变量排序。SHAP(Shapley 加性解释)可以进一步帮助解释单个变量对模型预测的贡献。
These techniques can help investigators identify candidate CPPs, understand parameter interactions, and prioritize follow-up experiments.
这些技术可以帮助研究者识别候选 CPP、理解参数交互作用,并为后续实验排定优先级。
However, feature importance is not equivalent to causal evidence. A parameter that predicts poor quality may be a proxy for another underlying factor. Scientific investigation and process-specific verification are therefore essential before designating a parameter as critical.
然而,特征重要性不等于因果证据。一个能预测质量不良的参数可能只是某个深层因素的代理变量。因此,在将某个参数指定为关键参数之前,必须进行科学调查和针对具体工艺的验证。
Multivariate Anomaly Detection 多变量异常检测
Unsupervised learning methods, including autoencoders and Isolation Forests, can identify unusual combinations of process variables.
无监督学习方法,包括自编码器与孤立森林,可以识别工艺变量的异常组合。
A batch may remain within individual statistical process control limits while exhibiting an abnormal multivariate pattern. AI can flag these combinations for investigation before they develop into a measurable quality failure.
一个批次可能每个单变量都停留在统计过程控制限内,却表现出异常的多变量模式。AI 可以在这些组合发展成可测量的质量失效之前将其标记出来供调查。
Context-Dependent Parameter Criticality 依赖情境的参数关键性
Parameter importance may depend on the operating context. A process variable may have little impact under normal conditions but become influential when raw material properties, equipment performance, or environmental conditions change.
参数的重要性可能取决于运行情境。某个工艺变量在正常条件下影响甚微,但在原料性质、设备性能或环境条件变化时可能变得有影响。
AI can help identify these conditional relationships and direct additional characterization studies toward potentially vulnerable regions of the process.
AI 可以帮助识别这些条件性关系,并把额外的表征研究引向工艺中潜在的脆弱区域。
Practical Implication 实践含义
AI-derived insights should be treated as a means of discovering and prioritizing candidate CPPs—not as an automatic replacement for process characterization.
AI 派生洞察应当被当作发现候选 CPP 并为其排序的手段,而不是工艺表征的自动替代品。
The appropriate workflow combines historical data analysis, scientific rationale, targeted experimentation, risk assessment, and documented approval through the pharmaceutical quality system.
恰当的工作流把历史数据分析、科学论证、针对性实验、风险评估以及经由药品质量体系的书面批准结合起来。
The result can be a more comprehensive understanding of process variability and a stronger evidence base for parameter classification.
其结果可以是对工艺变异性的更全面理解,以及为参数分类提供的更强证据基础。
二、CQA 与 CPP 关系建模 CQAs and CPPs Relationships Modeling
超越线性假设 Moving Beyond Linear Assumptions
Pharmaceutical development aims to understand how raw material attributes and process settings affect intermediate material and final drug product quality.
制药开发的目的是理解原料属性与工艺设定如何影响中间物料和最终药品的质量。
Relevant CQAs may include dissolution performance, impurity levels, particle size distribution, protein aggregation, glycosylation patterns, and potency.
相关的 CQA 可包括溶出性能、杂质水平、粒径分布、蛋白质聚集、糖基化谱和效价。
Conceptually, the final quality profile can be expressed as:
概念上,最终质量谱可以表示为:
CQA_final = f(CPP_1, ..., CPP_n, A_1, ..., A_m) + ε
CQA_final = f(CPP₁, …, CPPₙ, A₁, …, Aₘ) + ε
where:
其中:
· CPPi represents a process parameter.
· Ai represents a raw material or input attribute.
· f represents the relationship between inputs and product quality.
· ε represents unexplained variability and measurement error.
CPPᵢ 表示一个工艺参数。
Aᵢ 表示一个原料或输入属性。
f 表示输入与产品质量之间的关系。
ε 表示无法解释的变异与测量误差。
In complex manufacturing systems, the function f may involve nonlinear kinetics, threshold effects, time-dependent behavior, and interactions across multiple unit operations.
在复杂生产系统中,函数 f 可能涉及非线性动力学、阈值效应、时间依赖行为以及跨多个单元操作的交互作用。
A conventional linear model may not adequately represent these relationships, particularly when the process operates across a broad range of conditions.
常规线性模型可能不足以表达这些关系,尤其当工艺在很宽的条件范围内运行时。
机理与数据驱动的混合模型 Hybrid Mechanistic and Data-Driven Models
Hybrid modeling combines established scientific principles with AI-derived relationships.
混合建模把成熟的科学原理与 AI 派生关系结合起来。
Mechanistic components can represent mass and energy balances, heat transfer, mixing, reaction kinetics, or cell growth. Machine learning components can estimate unknown parameters, capture residual nonlinear behavior, or represent relationships that are difficult to model directly.
机理组件可以表达质量与能量衡算、传热、混合、反应动力学或细胞生长。机器学习组件可以估计未知参数、捕捉残余的非线性行为,或表达难以直接建模的关系。
This approach offers an important advantage: predictions can be informed by both observed data and established process knowledge.
这一方法有一个重要优势:预测可以同时由观测数据和既有的工艺知识共同支撑。
It can also reduce the risk of implausible extrapolation, although physical constraints do not automatically guarantee accurate predictions outside the model's validated domain.
它还可以降低不合理外推的风险,尽管物理约束并不能自动保证模型在验证域之外的预测仍然准确。
贝叶斯神经网络(BNN)与不确定性估计 Bayesian Neural Networks (BNNs) and Uncertainty Estimation
BNNs can represent predictive uncertainty rather than producing only a single estimated value.
BNN 可以表达预测的不确定性,而不只是给出单一估计值。
Two forms of uncertainty are particularly relevant:
两类不确定性尤其相关:
· Epistemic uncertainty: Uncertainty associated with limited data or incomplete model knowledge
· Aleatoric uncertainty: Variability inherent in the process or measurement system
认知不确定性:与数据有限或模型知识不完整相关的不确定性
偶然不确定性:工艺或测量系统固有的变异
Understanding uncertainty helps pharmaceutical scientists distinguish between predictions supported by strong evidence and predictions that require additional data, laboratory testing, or human review.
理解不确定性有助于药学科学家区分有强证据支撑的预测和需要补充数据、实验室检测或人工复核的预测。
This distinction becomes especially important when an AI model is used to support quality decisions.
当 AI 模型被用于支持质量决策时,这一区分尤其重要。
AI 赋能的过程分析技术(PAT) AI-Enabled Process Analytical Technology (PAT)
PAT provides opportunities to monitor critical process information in real time through techniques such as Near-Infrared (NIR) spectroscopy, Raman spectroscopy, and other inline or online measurements.
PAT 通过近红外(NIR)光谱、拉曼光谱以及其他在线(inline/online)测量技术,为实时监测关键工艺信息提供了机会。
Deep learning architectures, including one-dimensional Convolutional Neural Networks (1D-CNNs) and Transformer-based models, may extract useful patterns from complex spectral data.
深度学习架构,包括一维卷积神经网络(1D-CNN)和基于 Transformer 的模型,可以从复杂光谱数据中提取有用模式。
Potential applications include estimating material concentration, monitoring process progression, and detecting changes associated with product quality.
潜在应用包括估计物料浓度、监测工艺进程,以及检测与产品质量相关的变化。
Nevertheless, model performance depends on representative calibration data, suitable reference methods, instrument control, and robust management of spectral preprocessing and measurement variability.
尽管如此,模型性能取决于有代表性的校准数据、合适的参照方法、仪器控制,以及对光谱预处理和测量变异性的稳健管理。
实践含义 Practical Implication
AI can strengthen CQA–CPP mapping by revealing nonlinear relationships and helping quantify uncertainty. These findings should support, not bypass, scientific interpretation, experimental confirmation, and the documented establishment of the process understanding required for the intended regulatory use.
AI 可以通过揭示非线性关系和帮助量化不确定性来强化 CQA–CPP 映射。这些发现应当支撑而不是绕过科学解释、实验确认,以及为预期监管用途而书面建立的工艺理解。
资料来源:Robert Dream, Expanding the Pharmaceutical Quality Framework: Part 1 — Leveraging AI-Derived Insights Across CMC, Process Validation, and Quality Systems, ISPE iSpeak Blog, 2026-11-09。原文链接:ispe.org/pharmaceutical-engineering/ispeak/expanding-pharmaceutical-quality-framework-part-1-leveraging-ai
来源:小南AI实验室 · mp.weixin.qq.com